Nirvana Life Sciences

Nirvana Life Sciences: Psychedelics for Opioid Addiction Recovery and Pain Management

Nirvana Life Sciences (CSE:NIRV) was founded to develop novel therapeutic products derived from psychedelics.

The company has targeted two products for its first development phase. One product will focus on transitioning from opioids to non-addictive pain relief therapies and ideally prevents relapse. The second product will provide non-addictive pain relief. Nirvana Life Sciences began by acquiring the intellectual property (IP) behind these formulations and has since conducted its own research to advance them.

It has received a Section 56 Exemption from Health Canada, enabling them to legally conduct its research and development in Vancouver. Additionally, its new facility will be built to Level Nine Security Standards to safeguard its research. Pre-clinical research for its formulations have already begun. This research is being undertaken at the University of Camerino in Italy. This lab was granted special permission from the Italian government to work with psilocybin-based compounds. Reports from these trials are expected in Q3 2022.

Computer rendering of a three-dimensional braininvestingnews.com


Company Highlights

  • Nirvana Life Sciences is an innovative research and development company focused on novel formulations for opioid addiction and pain management that use psychedelic compounds.
  • The company is exclusively focused on products, rather than wellness retreats or psychotherapy programs like some of its competitors.
  • Nirvana Life Sciences’ first phase of development is targeting two products, one to aid in opioid addiction recovery and the other is targeting non-addictive pain management.
  • IP has been purchased from researchers who have extensively studied the effects of psychedelic compounds for medicinal purposes
  • The company is taking every precaution to operate legally and protect against potential criminal elements that may target its facilities
  • Pre-clinical research began in 2021 and the results are expected in Q3 2022 and will determine future developments
  • A strong team of doctors and visionaries lead the company, each bringing their specialty to the company to fully develop its products

This Nirvana Life Sciences company profile is part of a paid investor education campaign.*
NIRV:CC
The Conversation (0)
Nirvana Life Sciences

Nirvana Life Sciences

Psychedelics for Opioid Addiction Recovery and Pain Management

Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...

Interactive Chart

Latest Press Releases

Related News